- Home
- SE vs VRTX Comparison
SE vs VRTX Comparison
Compare SE & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SE
- VRTX
- Stock Information
- Founded
- SE 2009
- VRTX 1989
- Country
- SE Singapore
- VRTX United States
- Employees
- SE N/A
- VRTX N/A
- Industry
- SE Other Consumer Services
- VRTX EDP Services
- Sector
- SE Consumer Discretionary
- VRTX Technology
- Exchange
- SE Nasdaq
- VRTX Nasdaq
- Market Cap
- SE 109.8B
- VRTX 101.2B
- IPO Year
- SE 2017
- VRTX 1991
- Fundamental
- Price
- SE $187.00
- VRTX $387.15
- Analyst Decision
- SE Buy
- VRTX Buy
- Analyst Count
- SE 11
- VRTX 25
- Target Price
- SE $177.45
- VRTX $495.77
- AVG Volume (30 Days)
- SE 3.6M
- VRTX 1.5M
- Earning Date
- SE 11-11-2025
- VRTX 11-03-2025
- Dividend Yield
- SE N/A
- VRTX N/A
- EPS Growth
- SE N/A
- VRTX N/A
- EPS
- SE 1.95
- VRTX 14.07
- Revenue
- SE $19,379,246,000.00
- VRTX $11,418,800,000.00
- Revenue This Year
- SE $34.11
- VRTX $10.93
- Revenue Next Year
- SE $22.33
- VRTX $9.54
- P/E Ratio
- SE $95.67
- VRTX $27.48
- Revenue Growth
- SE 33.95
- VRTX 10.46
- 52 Week Low
- SE $78.51
- VRTX $362.50
- 52 Week High
- SE $199.30
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- SE 55.51
- VRTX 40.14
- Support Level
- SE $187.70
- VRTX $386.32
- Resistance Level
- SE $199.30
- VRTX $398.29
- Average True Range (ATR)
- SE 5.23
- VRTX 7.44
- MACD
- SE -0.99
- VRTX 1.40
- Stochastic Oscillator
- SE 53.21
- VRTX 5.05
About SE Sea Limited each representing one
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid C2C and B2C marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue generating game. Sea's third business, SeaMoney, provides lending, payment, digital banking, and insurance services.As of March 31, 2024, Forrest Xiaodong Li, the founder, chairman and CEO, owned 59.8% of voting power and 18.5% of issued shares. Tencent owned 18.2% of issued shares with no voting power.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.